Related Experiment Video

Updated: Jul 4, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Effector mechanisms of therapeutic antibodies against ErbB receptors

Matthias Peipp1, Michael Dechant, Thomas Valerius

  • 1Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University, Schittenhelmstr. 12, Kiel, Germany.

Current Opinion in Immunology
|July 1, 2008
PubMed

Insights

ErbB1 and ErbB2 are key targets for cancer therapy. Understanding their complex biology through structural studies can improve antibody and tyrosine kinase inhibitor (TKI) treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • ErbB1 and ErbB2 are validated targets for cancer treatment, with approved therapies including antibodies and tyrosine kinase inhibitors (TKIs).
  • The intricate biology of ErbB receptors in development and cancer presents challenges for optimizing targeted therapies.
  • Structural insights into ErbB receptors are crucial for advancing therapeutic strategies.

Purpose of the Study:

  • To review recent advances in understanding ErbB receptor structure and function.
  • To discuss the implications of these advances for improving ErbB-directed cancer therapies.
  • To highlight the mechanisms of action for ErbB therapeutic antibodies and TKIs.

Main Methods:

  • Review of crystallographic studies on ErbB receptors.
  • Analysis of structure-function relationships.
  • Discussion of therapeutic implications for antibodies and TKIs.

Main Results:

  • Crystallographic studies have enhanced the understanding of ErbB receptor structure and function.
  • Improved knowledge of ErbB biology aids in optimizing targeted therapy approaches.
  • Recent advances provide a basis for enhancing the efficacy of ErbB-directed treatments.

Conclusions:

  • Structural biology significantly contributes to advancing ErbB-targeted cancer therapies.
  • Further research into ErbB receptor mechanisms can lead to more effective treatments.
  • Optimizing antibody and TKI therapies relies on a deep understanding of ErbB receptor biology.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...